(Total Views: 258)
Posted On: 09/20/2017 5:42:45 PM
Post# of 72447
Worldwide Oral Mucositis Market Will Grow Steady at a Rate of 7% CAGR by 2023
Key players of Global Oral Mucositis market:
Some of the players operating for the oral mucositis are
Izun Pharmaceutical Ltd (US)
Shoreline Pharmaceuticals Inc. (USA)
Himalaya (India)
AMAG Pharmaceuticals Inc. (USA)
Kinnear Pharmaceuticals (US)
Celleutix Corporation(USA)
Soligenix Inc. (US)
Oragenics (US)
https://www.medgadget.com/2017/09/worldwide-o...-2023.html
Brilacidin for the Prevention of Severe Oral Mucositis
"Brilacidin has been granted Fast Track by the FDA, which makes it eligible for more frequent FDA meetings, as well as potentially accelerated approval and priority review. The Company also plans to submit Brilacidin for FDA Breakthrough Therapy designation in the treatment of OM if results similar to those observed, at interim, continue to be seen through the conclusion of the study, planned to be completed in 4Q2017."
http://www.ipharminc.com/new-blog/2017/8/7/br...-mucositis
Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis
About Oral Mucositis
"Oral Mucositis (OM) is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of Head and Neck Cancer. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and are more susceptible to bacterial infections, with severe cases leading to hospitalization and increased treatment costs of up to $25,000. Affecting over 500,000 people in the United States, there currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years."
http://www.ipharminc.com/press-release/2017/8...-mucositis
Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
Study showed a markedly reduced rate of Severe OM (WHO Grade ≥ 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent)
"These interim results suggest the potential for an even greater effective therapeutic response as formulation and dosing is further optimized,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix. "There currently is no existing preventative treatment available for OM patients in this population, with only limited therapies focusing on symptom relief."
http://www.ipharminc.com/press-release/2017/3...-treatment
Key players of Global Oral Mucositis market:
Some of the players operating for the oral mucositis are
Izun Pharmaceutical Ltd (US)
Shoreline Pharmaceuticals Inc. (USA)
Himalaya (India)
AMAG Pharmaceuticals Inc. (USA)
Kinnear Pharmaceuticals (US)
Celleutix Corporation(USA)
Soligenix Inc. (US)
Oragenics (US)
https://www.medgadget.com/2017/09/worldwide-o...-2023.html
Brilacidin for the Prevention of Severe Oral Mucositis
"Brilacidin has been granted Fast Track by the FDA, which makes it eligible for more frequent FDA meetings, as well as potentially accelerated approval and priority review. The Company also plans to submit Brilacidin for FDA Breakthrough Therapy designation in the treatment of OM if results similar to those observed, at interim, continue to be seen through the conclusion of the study, planned to be completed in 4Q2017."
http://www.ipharminc.com/new-blog/2017/8/7/br...-mucositis
Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis
About Oral Mucositis
"Oral Mucositis (OM) is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of Head and Neck Cancer. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and are more susceptible to bacterial infections, with severe cases leading to hospitalization and increased treatment costs of up to $25,000. Affecting over 500,000 people in the United States, there currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years."
http://www.ipharminc.com/press-release/2017/8...-mucositis
Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
Study showed a markedly reduced rate of Severe OM (WHO Grade ≥ 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent)
"These interim results suggest the potential for an even greater effective therapeutic response as formulation and dosing is further optimized,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix. "There currently is no existing preventative treatment available for OM patients in this population, with only limited therapies focusing on symptom relief."
http://www.ipharminc.com/press-release/2017/3...-treatment
(0)
(0)
